Business

Digitalization is expected to reform the European pharmaceutical industry. But it will also change perceptions towards technology and current regulatory skillsets.

Its latest acquisition adds to Merck’s arsenal of hemato-oncology candidates, with TERN-701 aiming to challenge Novartis's Scemblix.

The deal, which is expected to close in the first half of 2026, includes $2bn upfront plus $1bn in milestone related payments.

Samsung Bioepis’ explorations for an alternate semaglutide formulation will be powered by G2GBIO’s microsphere technology.

Digitalization is expected to reform the European pharmaceutical industry. But it will also change perceptions towards technology and current regulatory skillsets.

In the second part of our exclusive interview with Medicines for Europe leaders, Generics Bulletin delves into medicinal product regulation by environmental and chemical agencies, and the need to maintain the historical off-patent drug heritage in Europe.

Deal after deal, Formycon was inching toward closing the gap in its annual guidance. Still, it was not enough to meet the goal, as the German biosimilars developer’s preliminary financial report reveals.

Even Amneal, a prominent off-patent player, is not immune to generic competition, as its Parkinson’s disease drug Rytary is expected to take a hit.

Lupin is riding a wave of growth across most of its global markets, with biosimilars and other complex products filling its portfolio.

Biocon Biologics hinted about exploring the development of a higher concentration adalimumab biosimilar, now that it has full rights to the Hulio franchise.

Samsung Bioepis has signed off on another settlement for its Eylea biosimilar rival, opening up the US market from the start of 2027. While later than other competitors, for Bioepis this marks the resolution of all patent-related matters.

Just a few days after Alvotech announced global settlements for its Eylea rival, Samsung Bioepis has followed up with its own agreements with the originators.